Can Destroying Senescent Cells Treat Age-Related Disease? (March 1, 2020)
Working at the frontier of biotechnology and medicine, our mission is to develop therapeutics to extend the period of one’s life unburdened by disease. Our initial focus is on delivering localized therapy in ophthalmologic diseases, including diabetic macular edema and age-related macular degeneration, and age-related neurologic conditions.
Management
Members of UNITY’s management team have collectively advanced over 100 therapeutic candidates into human clinical trials and are responsible for over 10 FDA-approved medicines.
BOARD OF DIRECTORS
PAUL L. BERNS
Former President and Chief Executive Officer,
Anacor Pharmaceuticals, Inc.
MICHAEL SAMAR
Former Chief Financial Officer,
Assembly Biosciences, Inc.
NATHANIEL DAVID, PH.D.
Co-Founder,
UNITY Biotechnology
ANIRVAN GHOSH, PH.D.
Chief Executive Officer,
UNITY Biotechnology
KEITH R. LEONARD JR.
Chairman,
UNITY Biotechnology
GILMORE O’NEILL, M.B.
President and Chief Executive Officer,
Editas Medicine
MARGO ROBERTS, PH.D.
Former Chief Scientific Officer,
Lyell Immunopharma, Inc.
CAMILLE SAMUELS
Partner,
Venrock
Can Destroying Senescent Cells Treat Age-Related Disease? (March 1, 2020)
10 Breakthrough Technologies (February 26, 2020)
What If You Could Postpone The Diseases Commonly Associated With Getting Old? (February 18, 2020)
Is longevity more than a billionaire’s pipe-dream? (March 15, 2022)